Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Republicans and Democrats in Congress are reportedly close to striking a deal to delay the medical device tax enacted as part of Obamacare, but face opposition from the White House.
The delay, which would also hit pause on the so-called “Cadillac tax” on high-benefit health plans, is part of a major tax package being negotiated by legislators, The Hill reported. Read more
Arsenal Medical said it won a contract from the U.S. Army Medical Research and Materiel Command for more than $14 million to complete clinical and manufacturing development and regulatory submission for its ResQFoam.
Arsenal’s ResQFoam is a self-expanding biomaterial designed to be administered at the point of injury to stop blood loss in patients with severe internal bleeding in the abdomen due to life-threatening traumas. The material fills the wound and conforms to the abdominal cavity to control bleeding and can be removed before surgery, the company said. Read more
Medtronic said that its Active line of deep-brain stimulators won FDA approval for conditional, full-body MRI scans, claiming the devices as the only examples allowed on the U.S. market for full-body MR imaging.
The approval applies both to new Activa devices and to the roughly 43,000 U.S. patients already implanted with them, Fridley, Minn.-based Medtronic said. Read more